Out of the 18 patients enrolled, five achieved stable disease lasting greater than three months. Data from the study demonstrates that Panzem NCD (2ME2 or 2-methoxyestradiol), administered as a single agent in patients with platinum refractory epithelial ovarian cancer, resulted in one patient with a confirmed partial response of their CA-125.
Panzem NCD was well tolerated and no significant neuropathy, myelosuppression or thromboembolic side effects were reported. Three patients remained on study for more than six months and two of these patients are still on study.
Carolyn Sidor, vice president and chief medical officer, said: “Results from this study continue to demonstrate that Panzem NCD has modest activity and an excellent safety profile as a single agent in heavily pretreated and refractory ovarian cancer patients. The stage is now set for us to consider additional trials where Panzem NCD can be combined with approved agents in an attempt to provide clinical benefit to patients with advanced cancers.”